<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087334</url>
  </required_header>
  <id_info>
    <org_study_id>I 17403</org_study_id>
    <secondary_id>RPCI-I-17403</secondary_id>
    <secondary_id>ZENECA-IRUSIRES0414</secondary_id>
    <nct_id>NCT00087334</nct_id>
  </id_info>
  <brief_title>Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I/II Study of Capecitabine (XELODA®, Roche) Plus Oxaliplatin (Eloxatin®, Sanofi) Plus ZD 1893 (IRESSA®) in the Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may&#xD;
      stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining&#xD;
      capecitabine and oxaliplatin with gefitinib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine&#xD;
      when given together with oxaliplatin and gefitinib and to see how well they work in treating&#xD;
      patients with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of capecitabine when given in combination with&#xD;
           oxaliplatin and gefitinib in patients with metastatic colorectal cancer. (phase I)&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen. (phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety and toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the 1-year survival of patients treated with this regimen. (phase II)&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen. (phase II)&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, phase I, dose-escalation study of capecitabine&#xD;
      followed by a phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin IV&#xD;
           over 2 hours on day 1. Patients also receive oral gefitinib once daily beginning 5 days&#xD;
           before the initiation of capecitabine and oxaliplatin and continuing for the duration of&#xD;
           study treatment. Courses repeat every 21 days in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive oral capecitabine (at the MTD determined in phase I),&#xD;
           oxaliplatin IV, and oral gefitinib as in phase I.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the phase I portion of this&#xD;
      study within 1-12 months; and a total of 26 patients will be accrued for the phase II portion&#xD;
      of this study within 8-13 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to poor/low accrual&#xD;
  </why_stopped>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival (phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in (phase II)</measure>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed* colorectal cancer&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  The site of the primary tumor must have been confirmed endoscopically,&#xD;
                  radiologically, or surgically to be the colon or rectum NOTE: *Confirmation is&#xD;
                  not required for recurrent metastatic disease unless an interval of &gt; 5 years has&#xD;
                  elapsed between the initial primary surgery and the development of metastases&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ ULN&#xD;
&#xD;
          -  No unstable or uncompensated hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  No unstable or uncompensated renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable or uncompensated cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No evidence of clinically active interstitial lung disease&#xD;
&#xD;
               -  Asymptomatic patients with chronic stable radiographic changes are eligible&#xD;
&#xD;
          -  No unstable or uncompensated respiratory disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No known hypersensitivity to gefitinib or any of its excipients&#xD;
&#xD;
          -  No known hypersensitivity to platinum compounds, fluorouracil, or capecitabine&#xD;
&#xD;
          -  No severe or uncontrolled systemic disease&#xD;
&#xD;
          -  Able to receive oral medication&#xD;
&#xD;
          -  No known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          -  No known peripheral neuropathy ≥ grade 1&#xD;
&#xD;
               -  Absence of deep tendon reflexes as the sole neurological abnormality allowed&#xD;
&#xD;
          -  No other significant clinical disorder or laboratory finding that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma&#xD;
             in situ of the cervix (phase II only)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy for metastatic colorectal cancer (phase I)&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease (phase II)&#xD;
&#xD;
               -  Prior fluorouracil and leucovorin calcium in the adjuvant setting allowed&#xD;
                  provided the last treatment was administered more than 6 months before the&#xD;
                  development of metastatic disease&#xD;
&#xD;
          -  No prior irinotecan and oxaliplatin (phase II)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy for colorectal cancer&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery (e.g., laparotomy)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy (no unresolved chronic toxicity &gt; grade 2)&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No prior epidermal growth factor receptor inhibitor therapy (phase II)&#xD;
&#xD;
          -  No concurrent phenytoin, carbamazepine, rifampin, barbiturates, or Hypericum&#xD;
             perforatum (St. John's wort)&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent systemic therapy for colorectal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

